For more than 75 years, Grifols has been improving the health and well-being of people. Our patients are our priority, and our commitment to their health has enabled us to become a global healthcare leader with presence in more than 100 countries. The Grifols legacy embodies a spirit of innovation and a forward thinking approach and establish us as an international benchmark in the plasma collection market, the production of plasma derived therapies and transfusion medicine.
Grifols has three business divisions:
Bioscience brings together all plasma related activities including research, development, collection, production and sales of life-saving plasma derived therapies. Diagnostic provides innovative solutions to support safe and compatible transfusions, monitor therapies, and detect infectious and autoimmune diseases. Research novel technologies to further improve treatment outcomes and laboratory efficiency. Hospital specializes in non-biological pharmaceutical products. This division supplies hospitals with a wide range of pharmaceutical products and medical devices for use in hospital pharmacy, automated compounding, clinical nutrition and fluid therapy.

Company Growth (employees)
Type
Public
HQ
Sant Cugat Del Vallès, ES
Founded
1940
Size (employees)
16,808 (est)+13%
Grifols was founded in 1940 and is headquartered in Sant Cugat del Vallès, ES

Grifols Office Locations

Grifols has offices in Sant Cugat del Vallès, Clayton South, Kita Ward, Prague and in 10 other locations
Sant Cugat del Vallès, ES (HQ)
152 Avinguda de la Generalitat
Los Angeles, US
2410 Lillyvale Ave
Mississauga, CA
405 5060 Spectrum Way
Düdingen, CH
9 Bonnstrasse
Stockholm, SE
166 Sveavägen
Vicopisano, IT
15 Via Torino
Show all (14)

Grifols Financials and Metrics

Grifols Financials

USD

Market capitalization (02-Oct-2017)

5.7 b

Closing share price (02-Oct-2017)

21.9
Grifols's current market capitalization is $5.7 b.
Show all financial metrics

Grifols Market Value History

Traffic Overview of Grifols

Grifols Online and Social Media Presence

Grifols News and Updates

Plasma Therapy Market Report 2016 By Industry Size, Share & Key Drivers 2024

Orthopedic disorders are linked with aging and trauma, hence high growth in demand for minimally invasive therapies is anticipated, which in turn may boost the global plasma therapy market growth. Posted via Industry Today. Follow us on Twitter @IndustryToday

Global Blood Plasma Derivatives Market 2017 SK Plasma, Seraplex Inc., Grifols, CSL Limited

The overall info of the Blood Plasma Derivatives market provided within the report helps our consumer to form precise and correct selections so as to achieve most profit during this cutthroat competition within the world market. Posted via Industry Today. Follow us on Twitter @IndustryToday

Grifols Company Life and Culture

You may also be interested in